Home > Immunization & Vaccines > National Advisory Committee on Immunization (NACI) > The Recommended Use of the Multicomponent Meningococcal B (4CMenB) Vaccine in Canada > Text Equivalents
The line graph shows overall and serogroup specific incidence rates of IMD (per 100,000 population) in Canada by year, from 1995 to 2011. The overall incidence rate decreased from 1.04 in 1995 to 0.70 in 1998 and then increased again and peaked at 1.18 in 2001. The overall incidence decreased significantly to 0.74 in 2002. From 2003 to 2011, the overall incidence fluctuated with a range from 0.45 to 0.70. From 1995 to 2002, the overall trend of IMD was mainly driven by the trend of serogroup C. After the introduction of routine immunization programs for meningococcal C conjugate vaccine (MenC) in infants in 2002, incidence rate of serogroup C decreased significantly from 0.26 in 2002 to 0.01 in 2011. The incidence rate of serogroup B fluctuated from 1995 to 2011 with a mean of 0.31 (range 0.22-0.44). With the declining incidence of serogroup C, serogroup B now makes up the greatest proportion of reported IMD cases in Canada (62% due to serogroup B versus 2% due to serogroup C in 2011). From 1995 to 2011, serogroup Y and serogroup W-135 have stabilized at relatively low incidence with mean incidence rates of 0.09 and 0.03, respectively.